Rxsight, Inc. Stock Price, News & Analysis

RxSight, Inc. (NASDAQ: RXST), a leader in ophthalmic medical devices, will participate in the virtual J.P. Morgan Healthcare Conference on January 13, 2022, at 6:45 am PT / 9:45 am ET. This presentation will focus on their innovative Light Adjustable Lens system, which customizes visual acuity post-cataract surgery. Additionally, the lens now includes ActivShield technology for UV protection. Interested parties can access the live stream via the company’s website.

RxSight, Inc. (NASDAQ: RXST) has announced its participation in the virtual Ophthalmology Day at BTIG, scheduled for November 30, 2021, at 8:30 am PT / 11:30 am ET. The event will feature a fireside chat with the company’s management, and interested parties can access a live and archived webcast via the company’s website.

Specializing in ophthalmic medical devices, RxSight aims to enhance vision for cataract surgery patients with its innovative Light Adjustable Lens system, which includes ActivShield technology for UV protection.

RxSight, Inc. (NASDAQ: RXST) reported a strong third quarter in 2021, achieving revenue of $5.8 million, up 39% year-over-year and 18% sequentially. This growth was fueled by the sale of 31 Light Delivery Devices and 1,977 Light Adjustable Lenses. Gross profit increased to $1.3 million (23% of revenue), while operating expenses surged 50% to $14.5 million. The net loss for the quarter was $(12.7) million or $(0.68) per share. The company forecasts full-year 2021 revenue between $21.0 million and $21.4 million.

RxSight, Inc. announced it will report its third-quarter financial results on November 10, 2021, after market close. The management will discuss the results in a conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the call via live webcast or by phone. RxSight focuses on innovative ophthalmic devices, specifically the Light Adjustable Lens system, which enhances visual acuity after cataract surgery. The product features ActivShield technology for UV protection.

RxSight, Inc. reported a strong second quarter in 2021 with revenues of $4.9 million, an 81% increase compared to the same period last year. Key drivers included the sale of 25 Light Delivery Devices and 1,825 Light Adjustable Lenses. The company received FDA approval for its updated Light Adjustable Lens with ActivShield technology, enhancing patient compliance. Operating expenses rose 57% to $13.1 million, primarily due to increased staffing. The net loss narrowed to $(13.5) million, compared to $(17.0) million in Q2 2020. Cash on hand was $61.7 million as of June 30, 2021.

RxSight, Inc. (NASDAQ: RXST) has rescheduled its second quarter 2021 financial results announcement to September 9, 2021, after market close, in respect of the Rosh Hashanah holiday. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET that same day, open to investors via a live and archived webcast. RxSight specializes in ophthalmic devices, offering the first customizable intraocular lens technology aimed at enhancing post-cataract surgery visual acuity, now featuring ActivShield™ technology for added UV protection.

RxSight, Inc. (NASDAQ: RXST) will participate in the virtual Wells Fargo Healthcare Conference on September 10, 2021, at 12:00 PM ET. Investors can access a live and archived webcast via the Investors section of the company's website. RxSight focuses on enhancing patients' vision post-cataract surgery with its Light Adjustable Lens system, the first of its kind that allows customization for improved visual acuity. The system now includes ActivShield technology for UV protection, further innovating ophthalmic treatments.

RxSight, Inc. announced it will disclose its Q2 2021 financial results after market close on September 7, 2021. The management will engage in a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested investors can access both live and archived webcasts of the call via RxSight's investor portal. This announcement precedes the release of financial performance metrics and operational updates for their innovative Light Adjustable Lens system.

RxSight, Inc. (NASDAQ: RXST) announced the appointment of Steve Everly as Vice President of U.S. Sales on August 17, 2021. Everly will lead the expansion of the company's sales organization, focusing on increasing physician adoption of the Light Adjustable Lens system equipped with ActivShield™ technology. With extensive experience in the ophthalmic field, including roles at Johnson & Johnson Vision and Abbott Laboratories, his expertise is expected to drive momentum in RxSight's sales. The company aims to enhance patient care post-cataract surgery through its innovative technologies.